Sale!

AB-CHMINACA

140.002,600.00

Clear

Description

AB-CHMINACA

AB-CHMINACA

AB-FUBINACA is an indazole-based synthetic cannabinoid

AB-FUBINACA is an indazole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 .

AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.

AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.

This product is intended for research and forensic applications.

Technical Information

Formal NameN-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CAS Number1185887-21-1
Molecular FormulaC20H28N4O2
Formula Weight356.5
Purity≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569}
FormulationA crystalline solid
λmax210, 303 nm
SMILESO=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI CodeInChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
InChI KeyKJNZIEGLNLCWTQ-KRWDZBQOSA-N

AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.

AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.

This product is intended for research and forensic applications.

Technical Information

Formal NameN-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CAS Number1185887-21-1
Molecular FormulaC20H28N4O2
Formula Weight356.5
Purity≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569}
FormulationA crystalline solid
λmax210, 303 nm
SMILESO=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI CodeInChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
InChI KeyKJNZIEGLNLCWTQ-KRWDZBQOSA-N

AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.

AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.

This product is intended for research and forensic applications.

Technical Information

Formal NameN-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CAS Number1185887-21-1
Molecular FormulaC20H28N4O2
Formula Weight356.5
Purity≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569}
FormulationA crystalline solid
λmax210, 303 nm
SMILESO=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI CodeInChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
InChI KeyKJNZIEGLNLCWTQ-KRWDZBQOSA-N

Additional information

selecte-quantity

10 grams, 25 grams, 50 grams, 100 grams, 250 grams, 500 grams, 1000 grams

Reviews

There are no reviews yet.

Be the first to review “AB-CHMINACA”

Your email address will not be published. Required fields are marked *